Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Revenue, Income, and R&D Spending Dip in Q2

NEW YORK, July 26 - Symyx Technologies today reported a 9-percent dip in total revenue atop decreased net income and slightly trimmed R&D spending.

 

Total revenue for the period ended June 30 was $14 million compared with $15.4 million the company reported one year ago. Symyx blamed the reduction on a decrease in collaboration revenue to $9.4 million in the current second quarter from $10.6 million for the same period last year. The company said this kind of revenue represented some 67 percent of total revenue for the quarter.

 

Meantime, second-quarter revenue from products, royalties, and licenses was a combined $4.6 million for the quarter compared to $4.7 million for the same period in 2001, Symyx said.

 

The company spent $9.6 million in R&D in the current quarter, down from $10 million year over year.

 

Still, net income for the quarter fell to $684,000, or $.02 per share, compared to $1.7 million, or $.05 per share, reported in the same quarter last year.

 

Symyx said it had roughly $117.8 million in cash, cash equivalents, and short-term investments as of June 30.

 

Looking ahead, the company said it expects to post total combined annual revenues of between $65 million and $70 million, which is below the $80 million to $85 million Symyx originally expected to book by Dec. 31. The guidance is still about 10 percent above what the company brought in 2001, Symyx said.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.